Proof-of-concept experiments using CRISPR/Cas on Rett Syndrome patient iPSC lines have shown success in correcting MECP2 mutations [48] and in activating UBE3A in Angelman Syndrome [107]. This evidence concerns the gene UBE3A and Angelman syndrome.